Juan Li1, Min Zhao2, Mei Liu3, Kaixi Tang4, Guoxing Sun5. 1. Department of Critical Care Medicine, Taishan Sanatorium of Shandong Province Tai'an 271000, Shandong Province, China. 2. Department of Pharmacy, Weifang Yidu Central Hospital Weifang 262500, Shandong Province, China. 3. China Static Dispensing Center of Pharmaceutical and Mechanical Division, The Second People's Hospital of Dongying Dongying 257300, Shandong Province, China. 4. Department of Pharmacy, Shizhong Maternal and Child Health Hospital of Zaozhuang City Zaozhuang 277000, Shandong Province, China. 5. Department of Business, Cangzhou People's Hospital Yihe District Cangzhou 061000, Hebei Province, China.
Abstract
OBJECTIVE: To analyze the clinical effects of insulin glargine combined with repaglinide on the treatment of type 2 diabetes (T2D). METHODS: One hundred and twelve T2D patients were divided into two groups based on the treatment strategy, the control group (N=56) receiving insulin glargine and the experimental group (N=56) receiving insulin glargine combined with repaglinide. Clinical effects were analyzed and compared between the two groups. RESULTS: After treatment, the levels of fasting blood glucose (FBG), 2h-postprandial blood glucose (2h-PBG), and glycosylated hemoglobin of the experimental group were significantly lower than those of the control group (P<0.05). The levels of fasting C-peptide (FCP) and 2h-postprandial C-peptide (2h-PCP) of the experimental group were significantly higher than those of the control group (P<0.05) after treatment. Compared with the control group, the therapeutic efficacy was significantly higher (P<0.05), the time to normal blood glucose was notably shorter (P<0.05), and the insulin dosage was considerably lower in the experimental group (P<0.05). The incidence of adverse effects of the experimental group was significantly lower than that of the control group (P<0.05), and the treatment satisfaction of the experimental group was significantly higher than that of the control group (P<0.05). CONCLUSION: Insulin glargine combined with repaglinide is an effective and safe regimen in clinical practice, which can effectively control the blood glucose level, lower insulin dosage, and reduce adverse effects of T2D. AJTR
OBJECTIVE: To analyze the clinical effects of insulin glargine combined with repaglinide on the treatment of type 2 diabetes (T2D). METHODS: One hundred and twelve T2D patients were divided into two groups based on the treatment strategy, the control group (N=56) receiving insulin glargine and the experimental group (N=56) receiving insulin glargine combined with repaglinide. Clinical effects were analyzed and compared between the two groups. RESULTS: After treatment, the levels of fasting blood glucose (FBG), 2h-postprandial blood glucose (2h-PBG), and glycosylated hemoglobin of the experimental group were significantly lower than those of the control group (P<0.05). The levels of fasting C-peptide (FCP) and 2h-postprandial C-peptide (2h-PCP) of the experimental group were significantly higher than those of the control group (P<0.05) after treatment. Compared with the control group, the therapeutic efficacy was significantly higher (P<0.05), the time to normal blood glucose was notably shorter (P<0.05), and the insulin dosage was considerably lower in the experimental group (P<0.05). The incidence of adverse effects of the experimental group was significantly lower than that of the control group (P<0.05), and the treatment satisfaction of the experimental group was significantly higher than that of the control group (P<0.05). CONCLUSION: Insulin glargine combined with repaglinide is an effective and safe regimen in clinical practice, which can effectively control the blood glucose level, lower insulin dosage, and reduce adverse effects of T2D. AJTR
Authors: C Elizabeth Boudreau; Carlos E Dominguez; Jonathan M Levine; Joseph Mankin; Kimberly M Anderson; Andra K Voges; Geoffrey T Fosgate Journal: J Am Vet Med Assoc Date: 2018-04-01 Impact factor: 1.936